RIECKERMANN DEBUTS AT CPHI MIDDLE EAST 2024
Advancing pharma solutions through knowledge-sharing and technology showcase
Rieckermann proudly marked their inaugural participation at the CPHI Middle East 2024, building on the success of their award-winning booth at CPHI Southeast Asia earlier this year. Together with their industry partners, the company pledged to continue sharing knowledge of cutting-edge pharmaceutical technologies, signifying their collective commitment to advancing pharmaceutical solutions in the Middle East.
A highlight of Rieckermann’s participation was the insightful keynote presentation by Dr. Siew Leng Tai, Senior Biotech Specialist, on “Scaling Biosimilar Production: Technical Considerations & Challenges.” Held on Wednesday, December 11, at the Next-Gen Bio Theatre, Dr. Siew’s CME-accredited session covered critical topics, including:
- Optimization of upstream bioprocess for commercial-scale production
- Advancements in downstream processing and process intensification
- Regulatory challenges and comparability in biosimilar production
Throughout the event, Rieckermann actively engaged with visitors, exploring technological solutions and sharing insights and expertise. The on-site team was dedicated to understanding the unique needs of attendees and providing tailored solutions to address their challenges, fostering meaningful connections and collaborations.
CPHI Middle East was held from December 10 to 12, 2024 at the Riyadh Front Exhibition & Convention Center. With over 30,000 visitors and 400+ exhibitors from more than 100 countries, it is the region’s most comprehensive pharma gathering. Following this initial participation, Rieckermann looks forward to continuing their engagement with the Middle Eastern market and contributing to the region’s healthcare advancements.
